Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/06/2005US20050221287 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
10/06/2005US20050220897 nutraceuticals comprising indium sulfate, caffeine, cocoa powders, ethyl cellulose, and mixtures of zinc oxide, copper oxide, magnesium oxide, potassium iodide, and selenium, chromium and manganese amino acid chelates
10/06/2005US20050220859 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)
10/06/2005US20050220836 Drug delivery device
10/06/2005US20050220804 Increasing an immune response in an animal, comprising administering a compound (such as a carbohydrate, an antibiotic, a sugar, a protein, or an antibody) that binds a C-type lectin (but not the DEC-205 receptor) on the surface of a dendritic cell
10/06/2005US20050220799 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
10/06/2005US20050220778 Method for reduction of pathogenic bacteria in an aqueous environment
10/06/2005US20050220777 Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
10/06/2005US20050220776 Lactobacillus strains
10/06/2005US20050220771 Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods
10/06/2005US20050220768 Materials and methods for treating ocular-related disorders
10/06/2005US20050220763 Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-gamma
10/06/2005US20050220757 Chemokine mutants acting as chemokine antagonists
10/06/2005US20050220752 removing potassium from the gastrointestinal tract with a potassium-binding polymer; an alpha-fluoroacrylic acid polymer, or a difluoromaleic acid polymer crosslinked with vinylsulfonic acid, acrylic acid, vinyl phosphonate, vinyl-1,1-bisphosphonate, vinyl sulfonate, vinyl-1,2-disulfonate, itaconic aci
10/06/2005US20050220719 Nasal passage cleaning composition
10/06/2005US20050220715 Methods and compositions for improving drug safety
10/06/2005CA2610628A1 Combination therapy
10/06/2005CA2609972A1 Method and compositions for treatment of chronic neuropathic pain
10/06/2005CA2599543A1 Oral health care drink and method for reducing malodors
10/06/2005CA2561502A1 Marker gene for arthrorheumatism test
10/06/2005CA2561495A1 Truncated dance, dance complex and method of using these
10/06/2005CA2560988A1 Use of a phenothiazine derivative for preventing and/or treating hearing loss
10/06/2005CA2560928A1 Therapeutic agent for diabetes containing insulin resistance improving agent
10/06/2005CA2560927A1 Insulin resistance-improving agent
10/06/2005CA2560919A1 Uses of anti-ctla-4 antibodies
10/06/2005CA2559465A1 Herbal therapy for the treatment of asthma
10/06/2005CA2559458A1 Herbal therapy for the treatment of food allergy
10/06/2005CA2559266A1 Combinations comprising alpha-2-delta ligands
10/06/2005CA2558785A1 Drug-enhanced adhesion prevention
10/06/2005CA2558598A1 Combination therapy
10/06/2005CA2558346A1 Combination therapy
10/06/2005CA2557785A1 Hiv integrase inhibitors
10/06/2005CA2554860A1 Pharmaceutical composition and method for the transdermal delivery of magnesium
10/05/2005EP1582225A2 Drug delivery device
10/05/2005EP1582220A1 Composition for topical anesthesia
10/05/2005EP1582210A2 Compositions and methods for treating or preventing surgical adhesions
10/05/2005EP1581484A1 Hydroxamic acid derivatives having anti-inflammatory action
10/05/2005EP1581480A1 Cyclopentil-substituted glutaramide compounds as endopeptidasev inhibitors
10/05/2005EP1581307A2 Irs modulators
10/05/2005EP1581259A1 Method and material for specific proliferation promotion of lymphocyte sub-populations by means of a combination of an immunomodulator with a non-water-soluble natural product and a carrier
10/05/2005EP1581250A2 Oral formulations for proteins and polypeptides
10/05/2005EP1581240A1 Cholesterol-reducing agent containing an n-3 fatty acid
10/05/2005EP1581225A1 Combination therapy for the treatment of pain
10/05/2005EP1581216A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
10/05/2005EP1581215A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
10/05/2005EP1581211A1 Contact lens and eye drop rewetter compositions and their uses
10/05/2005EP1581210A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
10/05/2005EP1581203A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
10/05/2005EP1581200A2 Compositions and methods for nutrition supplementation
10/05/2005EP1581171A2 Antibodies against gpr64 and uses thereof
10/05/2005EP1581095A2 Therapeutic methods for reducing fat deposition and treating associated conditions
10/05/2005EP1511475B1 A herbal molecule as potential anti-leukemic drug
10/05/2005EP1325008B1 Piperazine derivatives
10/05/2005EP1263430B1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
10/05/2005EP1248654B1 Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
10/05/2005EP1233950B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
10/05/2005EP1230217B1 Positive modulators of nicotinic receptor agonists
10/05/2005EP1202733B1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
10/05/2005EP1124571B1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia
10/05/2005EP1083887B1 Pharmaceutical compositions for the treatment of ulcers
10/05/2005EP1001783B1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
10/05/2005EP0862455A4 Interferon-polymer conjugates and process for preparing the same
10/05/2005CN1678734A Differentiation modulating agents and uses therefor
10/05/2005CN1678628A Stress proteins and peptides and methods of use thereof
10/05/2005CN1678623A A robust, inducible cardiac preferred expression system for transgenesis
10/05/2005CN1678621A Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
10/05/2005CN1678612A Viral inhibitors
10/05/2005CN1678610A New quinuclidine amide derivatives
10/05/2005CN1678608A New neuropeptide y y5 receptor antagonists
10/05/2005CN1678350A Remedy
10/05/2005CN1678348A Compositions and methods for therapeutic treatment
10/05/2005CN1678342A Treatment for eye disorder
10/05/2005CN1678334A New plant based agents as bioavailability/bioefficacy enhancers for drugs and nutraceuticals
10/05/2005CN1678326A 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
10/05/2005CN1678324A Estrogen replacement regimen
10/05/2005CN1678317A 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(NK-1) antagonists for the treatment of emesis, depression, anxiety and cough
10/05/2005CN1678313A Therapeutic treatment for the metabolic syndrome and type 2 diabetes
10/05/2005CN1678309A Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
10/05/2005CN1678304A PKC activation as a means for enhancing aAPP-a secretion and improving cognition using bryostatin type compounds
10/05/2005CN1678299A Composition based on triethyl citrate for the treatment of bacterial infections of the skin
10/05/2005CN1678298A Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
10/05/2005CN1678188A Nucleic acid compositions for stimulating immune responses
10/05/2005CN1676165A In vivo slow-releasing anticancer medicinal composition
10/05/2005CN1676121A Slow-release micro-ball formulation for tissue, organ local therapy, and its preparing method and use
10/05/2005CN1221544C Pyrazole cyclic AMP-specific PDE inhibitors
10/05/2005CN1221534C Substited 8-arylquinoline phosphodiesterase-4 inhibitors
10/05/2005CN1221281C Oral, nasal and pulmonary dosage formulations of copolymer1
10/05/2005CN1221259C Preparation method of medicine for curing urteriosclerosis by using CS-866, losartan and candisartan
10/05/2005CN1221254C New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
10/05/2005CN1221248C Preparation method for antibiotics composition
10/05/2005CN1221237C Composition for treatment of scars skin disease
10/05/2005CN1221190C Composition and method for smoke detoxification
10/04/2005US6952650 Modulators of ribosomal function and identification thereof
10/04/2005US6951923 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy
10/04/2005US6951890 Preventing and/or treating cardiovascular disease and/or associated heart failure
10/04/2005US6951888 Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions
10/04/2005US6951871 Indole derivatives useful as histamine H3 antagonists
10/04/2005US6951868 Central nervous system disorders, gastrointestinal disorders;side effect reduction
10/04/2005US6951860 Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders
10/04/2005US6951859 Anticancer agents; diseases associated with signal trans-duction pathways operating through growth factor receptors
1 ... 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 ... 1151